NEWS
GE HEALTHCARE SHOWCASES LATEST AI-ENHANCED CARDIOLOGY SOLUTIONS TO ENABLE REAL-TIME CARDIAC IMAGING AND ASSESSMENTS AT THE POINT OF CARE AT ESC 2024
“ With diseases of the heart and blood vessels representing nearly one-third of all global deaths , innovation within cardiac diagnostics and treatment is one of our top priorities as a healthcare company ,” said Phil Rackliffe , President and CEO of Ultrasound and Image Guided Therapies , GE HealthCare . “ The integration of Caption AI on Vscan Air SL is a major step toward helping more users confidently capture diagnostic-quality images to inform clinical decisions when time is of the essence . With the recent CE mark , we ’ re eager to bring this technology to more healthcare providers around the world .”
GE HealthCare has announced the CE marks of its Vscan
Air SL wireless handheld ultrasound system with Caption AI ( Vscan Air SL with Caption AI ), an Artificial Intelligence ( AI ) -driven software for rapid cardiac assessments at the point of care , as well as ECG-less Cardiac computed tomography ( CT ) scanning on its Revolution Apex platform , which allows clinicians to acquire cardiac images without the aid of the patients ’ electrocardiogram ( ECG ) signal / trace . Both technologies were showcased at the European Society of Cardiology ( ESC ) Congress , in London last month .
JOHNSON & JOHNSON TO ACQUIRE V-WAVE
Johnson & Johnson has announced that it has entered into a definitive agreement to acquire V-Wave , a privately-held company focused on developing innovative treatment options for patients with heart failure . Under the terms of the agreement , Johnson & Johnson will acquire V-Wave for an upfront payment of US $ 600 million , subject to customary adjustments , with the potential for additional regulatory and commercial milestone payments up to approximately US $ 1.1 billion . V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech .
The planned acquisition of V-Wave will extend Johnson & Johnson MedTech ’ s position as an innovation leader in addressing cardiovascular disease . It will further accelerate its shift into high-growth and highopportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists .
Tim Schmid , Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech , said : “ We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease . We recognise the importance of identifying more diverse and effective treatments for heart failure , and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs .” �
12 www . intelligenthealth . tech